Tru Niagen is a commercially available dietary supplement whose active ingredient is nicotinamide riboside chloride, a form of vitamin B3 that the body converts into nicotinamide adenine dinucleotide, commonly known as NAD+. NAD+ is a molecule every cell uses for energy metabolism, DNA repair, and signaling, and its levels decline with age. The supplement has been studied in multiple human clinical trials, with consistent evidence that it raises blood NAD+ levels in a dose-dependent manner, though whether that translates into meaningful health improvements is a more complicated story.
How Nicotinamide Riboside Raises NAD+
Your cells can make NAD+ from several precursors, including plain niacin (vitamin B3), nicotinamide, tryptophan, and nicotinamide riboside (NR). What makes NR stand out is its route into the cell. After you swallow an NR supplement, cells use an enzyme called nicotinamide riboside kinase to phosphorylate NR directly into nicotinamide mononucleotide (NMN), which is then converted to NAD+. A single-dose study in a human volunteer confirmed that NR is orally bioavailable, with cellular NAD+ metabolites rising measurably within a few hours of ingestion.1Nature Communications. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
In animal and cell studies, NR supplementation has been shown to activate a family of proteins called sirtuins (SIRT1 and SIRT3 in particular), which regulate oxidative metabolism and mitochondrial function. Mice fed NR on a high-fat diet were protected from the metabolic damage that diet normally causes.2Cell Metabolism. Nicotinamide riboside uniquely increases NAD+ bioavailability, modulating metabolic and mitochondrial functions NR also stimulates the creation of new mitochondria and triggers protective stress responses within them.3PubMed Central. Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential These cellular findings are what originally generated excitement about NR as an anti-aging supplement, though translating cell-culture and mouse results to humans has proven difficult.
What the Human Dosing Trials Actually Show
The most consistent finding across human trials is that NR reliably boosts blood NAD+ levels. In a randomized, placebo-controlled trial of healthy overweight adults, daily doses of 100 mg, 300 mg, and 1,000 mg raised whole-blood NAD+ by roughly 22%, 51%, and 142% respectively within two weeks. Those increases held steady through eight weeks of continued supplementation.4PubMed Central. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults A separate open-label study using 1,000 mg twice daily found that every participant’s blood NAD+ rose, with individual increases ranging from about 35% to 168% above baseline.5PLOS ONE. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers
In a Parkinson’s disease safety trial using a much higher dose of 3,000 mg daily, whole-blood NAD+ levels jumped roughly 3.7-fold, along with increases in related metabolites like NADH and NADP+.6Nature Communications. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease So if the goal is simply to increase the amount of NAD+ circulating in your blood, NR works. The question that matters for most people is whether higher NAD+ levels produce tangible health benefits.
Cardiovascular and Blood Pressure Research
One area where researchers have been hopeful is cardiovascular health, particularly blood pressure and arterial stiffness. An ongoing trial at the University of Colorado has been designed to test whether NR supplementation lowers systolic blood pressure and reduces aortic stiffness in middle-aged and older adults, with the expectation that both would decrease.7PubMed Central. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults Early data from a small crossover trial of healthy middle-aged and older adults showed that NR supplementation at 1,000 mg per day tended to lower resting systolic blood pressure by a few points, though the study was not powered to confirm this as a definitive effect.
A related trial using NMN (a close chemical cousin of NR that shares the same downstream pathway to NAD+) found that arterial stiffness trended lower in the supplemented group, and the reduction was significant specifically in participants who had above-average body mass index or elevated blood glucose at baseline.8Scientific Reports. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial The cardiovascular research is still early-stage. Nothing published so far would justify taking NR specifically to treat high blood pressure, but the direction of the findings has been enough to keep clinical trials going.
Brain Health and Neurodegeneration
Some of the more interesting human data come from neurology. In a study of people with Parkinson’s disease, oral NR supplementation raised NAD+ levels not just in blood but in plasma vesicles of neuronal origin, which serve as a rough window into what is happening in brain cells. Participants who took NR had lower levels of amyloid-beta 42 (a protein fragment associated with Alzheimer’s pathology) and reduced activity of inflammatory signaling molecules in those same vesicles.9PubMed Central. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin
In the NR-SAFE trial, which specifically tested safety at the high dose of 3,000 mg daily in Parkinson’s patients, NR was well tolerated and substantially boosted NAD+ and its related metabolites in participants’ blood.6Nature Communications. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease These are biomarker changes, not clinical outcomes. Nobody has yet shown that NR makes Parkinson’s symptoms better or slows cognitive decline. But the fact that an oral supplement can measurably change neuronal biomarkers in a favorable direction is noteworthy and has spurred larger follow-up trials.
Where NR Has Not Delivered in Humans
For all the promise in animal models, several well-designed human trials have come up empty on metabolic endpoints. A placebo-controlled trial in obese men found that 12 weeks of NR supplementation at 2,000 mg per day did not improve insulin sensitivity, resting energy expenditure, fat oxidation, or body composition.10The American Journal of Clinical Nutrition. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects A companion study from the same research group examined pancreatic function in nondiabetic obese men and found that NR had no effect on fasting glucose, glucose tolerance, insulin secretion, or glucagon levels.11The Journal of Clinical Endocrinology & Metabolism. Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity
Similarly, a trial in healthy middle-aged and older adults found that NR supplementation at 1,000 mg per day did not improve skeletal muscle mitochondrial function, mitochondrial content, or the activity of the electron transport chain, despite raising blood NAD+ levels.12Cell Reports. Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults One bright spot in muscle research came from a crossover study in older adults that found NR improved isometric peak torque by about 8% and reduced fatigue by roughly 15%, though it had no effect on aerobic capacity or concentric strength.13PubMed. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study
The pattern across these trials is worth sitting with. NR reliably raises NAD+. The cells in your body measurably have more of this key molecule. Yet for many of the outcomes people care about, like losing weight, improving blood sugar, or boosting exercise performance, the extra NAD+ has not produced clear benefits in human studies. The gap between animal data and human results is one of the honest frustrations of this field.
Inflammation Effects Are Mixed
Chronic low-grade inflammation is thought to contribute to age-related diseases, and researchers have tested whether boosting NAD+ could help tamp it down. A review of clinical studies found that NR reduced circulating levels of IL-6, one of the body’s key inflammatory signaling molecules, in two of three trials that measured it. NR also lowered gene expression of IL-6 and IL-18 in immune cells in one study, and reduced levels of interferon beta in monocytes in another. However, effects on other inflammatory markers like TNF-alpha were inconsistent.14PubMed Central. The Clinical Effects of Nicotinamide Riboside on Inflammatory Parameters
A small pilot trial in people with chronic kidney disease added some nuance. NR supplementation raised levels of IL-2, a molecule that plays a role in immune regulation, compared to placebo.15PubMed Central. A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in CKD Whether that is helpful or neutral depends on context; IL-2 is not straightforwardly an inflammatory marker. The inflammation picture, in other words, is not clean enough for anyone to claim NR is an anti-inflammatory supplement based on current evidence.
Liver Health Findings Remain Preclinical
Some of the strongest-looking data on NR involve liver disease, but almost all of it comes from animal models. In mice fed alcohol, NR treatment activated the sirtuin-dependent pathways that protect mitochondria, reduced oxidative stress, and decreased fat accumulation in liver cells. When sirtuin 1 was experimentally knocked out, NR lost its protective effect, confirming the mechanism depends on that pathway.16PubMed Central. Nicotinamide riboside attenuates alcohol induced liver injuries via activation of SirT1/PGC-1α/mitochondrial biosynthesis pathway
In a mouse model of nonalcoholic fatty liver disease driven by a high-fat diet, NR reduced weight gain, liver fat, inflammation, insulin resistance, and fibrosis. Those effects depended on a hormone called irisin, produced by a gene called Fndc5; when that gene was knocked out, the benefits disappeared.17PubMed Central. NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin These findings are mechanistically elegant, but no randomized clinical trial has yet tested whether NR improves liver outcomes in humans with fatty liver disease. That gap matters if you are considering the supplement for this purpose.
Safety Profile and Side Effects
Across published human trials, NR has been consistently well tolerated. The eight-week dose-ranging trial in overweight adults found no significant differences in adverse events between NR and placebo at any dose tested, including 1,000 mg per day, and no reports of flushing, the uncomfortable skin reaction commonly associated with high-dose niacin.4PubMed Central. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults The NR-SAFE trial in Parkinson’s patients, which pushed the dose up to 3,000 mg daily, also found the supplement to be safe over its study period.6Nature Communications. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease
The most commonly reported side effects in trials are mild and gastrointestinal: nausea, bloating, and occasional diarrhea, typically at higher doses. Some participants have noted mild headaches or skin flushing, though the flushing reported with NR is far less severe than what people experience with nicotinic acid (the form of niacin used to treat cholesterol). There is no evidence of serious organ toxicity in published studies to date.
One area where caution is warranted involves cancer. Because NAD+ is a fuel source for all rapidly dividing cells, there is a theoretical concern that flooding the body with extra NAD+ could feed existing tumors. A review article flagged this explicitly, noting that the high energy requirements of certain diseases like cancer mean that elevating NAD+ or overexpressing sirtuins could conceivably promote neoplasm growth.18PubMed Central. Nicotinamide adenine dinucleotide and the sirtuins caution: Pro-cancer functions No human study has shown that NR supplementation causes or worsens cancer, but the biology of NAD+ makes this a reasonable precaution. People with active malignancies should discuss NR supplementation with their oncologist.
Dosage in Practice
Tru Niagen is sold in capsule form, with the standard product containing 300 mg of nicotinamide riboside chloride per capsule. The manufacturer’s label recommends one capsule daily. This aligns with the dose range shown to meaningfully raise NAD+ in human trials, where 300 mg per day produced a roughly 50% increase in whole-blood NAD+ that held over several weeks.4PubMed Central. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
Some users take higher doses, and clinical trials have tested up to 2,000 mg per day in metabolic studies and 3,000 mg per day in the Parkinson’s safety trial. The dose-response curve for NAD+ elevation appears to flatten somewhat at higher intakes; going from 300 mg to 1,000 mg roughly tripled the NAD+ boost, but there is no indication that tripling the dose again yields a proportionally larger effect. For most people, the 300 mg standard dose is a reasonable starting point. There is no regulatory body that has established an official tolerable upper intake level specifically for NR, as it is classified as a dietary supplement rather than a drug.
How NR Compares to NMN
The supplement most commonly compared to NR is nicotinamide mononucleotide, or NMN. Both are precursors to NAD+, and NMN is actually one step closer to NAD+ in the metabolic pathway. NR gets converted to NMN inside cells before becoming NAD+, so some people reason that taking NMN directly would be more efficient. In practice, the comparison is muddied by the fact that NMN is a larger molecule that likely gets broken down into NR or nicotinamide before crossing cell membranes, meaning the “shortcut” may not work the way it seems on paper.
The key practical difference is regulatory. Tru Niagen’s NR has been through FDA new dietary ingredient notification and has multiple published human safety and pharmacokinetic trials. NMN’s regulatory status in the United States has been more turbulent, with the FDA at one point asserting that NMN could not be marketed as a dietary supplement because it was being investigated as a drug. Head-to-head human trials directly comparing NR and NMN are scarce, and no study has convincingly shown that one raises NAD+ more effectively or produces better health outcomes than the other.
What “Raising NAD+” Does and Does Not Mean for Aging
The marketing around Tru Niagen leans heavily on the concept of cellular aging, and it is true that NAD+ decline is a well-documented feature of getting older. The logic seems compelling: NAD+ drops as you age, NR raises NAD+, so NR should reverse some aspect of aging. But this reasoning confuses a biomarker with a treatment target. Just because NAD+ declines during aging does not mean that forcing it back up reverses the processes that caused the decline or the damage accumulated alongside it.
The human evidence to date paints a picture of a supplement that reliably changes a blood measurement without reliably changing the outcomes people care about. Insulin sensitivity did not improve in obese men. Muscle mitochondrial function did not budge in older adults. Body composition did not shift. Blood sugar did not change. There are glimmers of promise in specific niches, like neuronal biomarkers in Parkinson’s patients and modest improvements in muscle fatigue resistance in older adults, but these are far from the broad anti-aging effect the supplement’s branding implies.
None of this means NR is worthless. It means the science has not yet caught up with the marketing. Some researchers suspect that NR may be most beneficial in people who start with especially low NAD+ levels, such as those with chronic disease, metabolic dysfunction, or advanced age, rather than in healthy adults whose NAD+ levels are merely slightly lower than they were at twenty. That hypothesis is still being tested, and the honest answer for now is that Tru Niagen is a well-tolerated supplement that does what it claims biochemically but has not yet proven it does what most buyers hope for clinically.
Why the Flushing Difference Matters
If you have ever taken high-dose niacin for cholesterol, you know the flush: an intense burning, reddening sensation across the face and chest caused by prostaglandin release in the skin. That reaction is the main reason many people abandon niacin therapy despite its effectiveness at raising HDL cholesterol. NR avoids this pathway entirely because it is metabolized differently. Where niacin binds to a receptor in skin cells that triggers prostaglandin release, NR enters the NAD+ synthesis route through kinase-mediated phosphorylation without activating that receptor. The absence of flushing in every published NR trial, even at doses of 3,000 mg per day, is a genuine pharmacological advantage over nicotinic acid as a means of supporting NAD+ metabolism.4PubMed Central. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults This does not make NR a replacement for niacin in treating dyslipidemia, since NR has not been shown to have the same cholesterol-modifying effects, but it removes the most common barrier people face with B3 supplementation more broadly.